Clothiapine
As of the edition of 20 October 2026, Clothiapine is a small molecule: marketed, first approved in 1967 (CH); acts on DRD4, HTR2A and HTR2B and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1968
- Kind
- Small molecule
- Brand name
- Entumin
- First approved
- 10 November 1967 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Laboratoires Juvise Pharmaceuticals; 2 holders in all
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| HTR3E | 5-hydroxytryptamine receptor 3E | A5X5Y0 |
| HTR3B | 5-hydroxytryptamine receptor 3B | O95264 |
| DRD4 | Dopamine receptor D4 | P21917 |
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
| HTR2C | 5-hydroxytryptamine receptor 2C | P28335 |
| HTR2B | 5-hydroxytryptamine receptor 2B | P41595 |
| HTR3A | 5-hydroxytryptamine receptor 3A | P46098 |
| HTR3D | 5-hydroxytryptamine receptor 3D | Q70Z44 |
| HTR3C | 5-hydroxytryptamine receptor 3C | Q8WXA8 |